Cargando…

Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern

OBJECTIVES: Antigen rapid diagnostic tests (Ag-RDTs) play an important role in the diagnosis of SARS-CoV-2. They are easier, quicker, and less expensive than the ‘reference standard’ RT-PCR and therefore widely in use. Reliable clinical data with respect to Ag-RDT performance in SARS-CoV-2 Omicron v...

Descripción completa

Detalles Bibliográficos
Autores principales: Bornemann, Linus, Kaup, Olaf, Kleideiter, Johannes, Ruprecht, Bertram, Hoyer, Annika, Panning, Marcus, Bornemann, Reinhard, Wehmeier, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181871/
https://www.ncbi.nlm.nih.gov/pubmed/37182639
http://dx.doi.org/10.1016/j.cmi.2023.05.009
_version_ 1785041668769054720
author Bornemann, Linus
Kaup, Olaf
Kleideiter, Johannes
Ruprecht, Bertram
Hoyer, Annika
Panning, Marcus
Bornemann, Reinhard
Wehmeier, Michael
author_facet Bornemann, Linus
Kaup, Olaf
Kleideiter, Johannes
Ruprecht, Bertram
Hoyer, Annika
Panning, Marcus
Bornemann, Reinhard
Wehmeier, Michael
author_sort Bornemann, Linus
collection PubMed
description OBJECTIVES: Antigen rapid diagnostic tests (Ag-RDTs) play an important role in the diagnosis of SARS-CoV-2. They are easier, quicker, and less expensive than the ‘reference standard’ RT-PCR and therefore widely in use. Reliable clinical data with respect to Ag-RDT performance in SARS-CoV-2 Omicron variants of concern (VOCs) are limited. Consequently, the objective of this study was to determine the impact different VOCs—especially Omicron—have on the clinical performance of an Ag-RDT. METHODS: We compared the clinical performance of the Sofia SARS-CoV-2 Ag-RDT to RT-PCR in a real-world, single-centre study in a clinical point-of-care setting in patients admitted to a large hospital via the emergency department from 2 November 2020 to 4 September 2022. RESULTS: Among 38 434 Ag-RDT/RT-PCR tandems taken, 1528 yielded a SARS-CoV-2 positive RT-PCR test result, with a prevalence of 4.0% (95% CI, 3.8–4.2). Overall sensitivity of the Ag-RDT was 63.7% (95% CI, 61.3–66.1) and overall specificity was 99.6% (95% CI, 99.5–99.6). Ag-RDT sensitivity was dependent on viral load (VL), because the sensitivity increased to 93.2% (95% CI, 91.5–94.6) in samples with a VL > 10(6) SARS-CoV-2 copies/mL. Furthermore, the Ag-RDT was more sensitive in men, and older patients. Variant-dependent sensitivity assessment showed that the sensitivity was significantly lower in Omicron-VOC (64.1%; 95% CI, 60.5–67.6) compared with SARS-CoV-2 wild-type samples (70.0%; 95% CI, 59,8–78,6) (binomial test; p value < 0.001). Analysing the limits of detection showed a 27 times higher 95% limit of detection for the Omicron-VOC BA.5 compared with the SARS-CoV-2 wild-type. DISCUSSION: Ag-RDT sensitivity for detection of patients with lower VLs and with Omicron-VOC is reduced, limiting the effectiveness of Ag-RDTs. However, Ag-RDTs are still an unreplaceable tool for widely available, quick, and inexpensive point-of-care SARS-CoV-2 diagnostics.
format Online
Article
Text
id pubmed-10181871
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-101818712023-05-15 Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern Bornemann, Linus Kaup, Olaf Kleideiter, Johannes Ruprecht, Bertram Hoyer, Annika Panning, Marcus Bornemann, Reinhard Wehmeier, Michael Clin Microbiol Infect Original Article OBJECTIVES: Antigen rapid diagnostic tests (Ag-RDTs) play an important role in the diagnosis of SARS-CoV-2. They are easier, quicker, and less expensive than the ‘reference standard’ RT-PCR and therefore widely in use. Reliable clinical data with respect to Ag-RDT performance in SARS-CoV-2 Omicron variants of concern (VOCs) are limited. Consequently, the objective of this study was to determine the impact different VOCs—especially Omicron—have on the clinical performance of an Ag-RDT. METHODS: We compared the clinical performance of the Sofia SARS-CoV-2 Ag-RDT to RT-PCR in a real-world, single-centre study in a clinical point-of-care setting in patients admitted to a large hospital via the emergency department from 2 November 2020 to 4 September 2022. RESULTS: Among 38 434 Ag-RDT/RT-PCR tandems taken, 1528 yielded a SARS-CoV-2 positive RT-PCR test result, with a prevalence of 4.0% (95% CI, 3.8–4.2). Overall sensitivity of the Ag-RDT was 63.7% (95% CI, 61.3–66.1) and overall specificity was 99.6% (95% CI, 99.5–99.6). Ag-RDT sensitivity was dependent on viral load (VL), because the sensitivity increased to 93.2% (95% CI, 91.5–94.6) in samples with a VL > 10(6) SARS-CoV-2 copies/mL. Furthermore, the Ag-RDT was more sensitive in men, and older patients. Variant-dependent sensitivity assessment showed that the sensitivity was significantly lower in Omicron-VOC (64.1%; 95% CI, 60.5–67.6) compared with SARS-CoV-2 wild-type samples (70.0%; 95% CI, 59,8–78,6) (binomial test; p value < 0.001). Analysing the limits of detection showed a 27 times higher 95% limit of detection for the Omicron-VOC BA.5 compared with the SARS-CoV-2 wild-type. DISCUSSION: Ag-RDT sensitivity for detection of patients with lower VLs and with Omicron-VOC is reduced, limiting the effectiveness of Ag-RDTs. However, Ag-RDTs are still an unreplaceable tool for widely available, quick, and inexpensive point-of-care SARS-CoV-2 diagnostics. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. 2023-05-12 /pmc/articles/PMC10181871/ /pubmed/37182639 http://dx.doi.org/10.1016/j.cmi.2023.05.009 Text en © 2023 Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Bornemann, Linus
Kaup, Olaf
Kleideiter, Johannes
Ruprecht, Bertram
Hoyer, Annika
Panning, Marcus
Bornemann, Reinhard
Wehmeier, Michael
Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern
title Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern
title_full Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern
title_fullStr Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern
title_full_unstemmed Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern
title_short Virus variant-specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on Omicron variants of concern
title_sort virus variant-specific clinical performance of a sars-cov-2 rapid antigen test with focus on omicron variants of concern
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10181871/
https://www.ncbi.nlm.nih.gov/pubmed/37182639
http://dx.doi.org/10.1016/j.cmi.2023.05.009
work_keys_str_mv AT bornemannlinus virusvariantspecificclinicalperformanceofasarscov2rapidantigentestwithfocusonomicronvariantsofconcern
AT kaupolaf virusvariantspecificclinicalperformanceofasarscov2rapidantigentestwithfocusonomicronvariantsofconcern
AT kleideiterjohannes virusvariantspecificclinicalperformanceofasarscov2rapidantigentestwithfocusonomicronvariantsofconcern
AT ruprechtbertram virusvariantspecificclinicalperformanceofasarscov2rapidantigentestwithfocusonomicronvariantsofconcern
AT hoyerannika virusvariantspecificclinicalperformanceofasarscov2rapidantigentestwithfocusonomicronvariantsofconcern
AT panningmarcus virusvariantspecificclinicalperformanceofasarscov2rapidantigentestwithfocusonomicronvariantsofconcern
AT bornemannreinhard virusvariantspecificclinicalperformanceofasarscov2rapidantigentestwithfocusonomicronvariantsofconcern
AT wehmeiermichael virusvariantspecificclinicalperformanceofasarscov2rapidantigentestwithfocusonomicronvariantsofconcern